CLINICAL VALUE OF CELL CONTENT WITH ISOLATED INTERSTITIAL DELetion 13q14 IN CHRONIC LYMPHATIC LEUKEMIA
Tamara Pavlovna ZAGOSKINA1, Ekaterina Nikolaevna ZOTINA2
1Kirov State Medical University of the Ministry of Healthcare of the Russian Federation
2Kirov Scientific Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Keywords: хронический лимфолейкоз, делеция 13q14, клинический исход, прогноз, chronic lymphocytic leukemia, 13q14 deletion, clinical outcome, prognosis
Abstract
Currently, it is urgent to search for new prognostic factors that improve the stratification of patients into risk groups and allow the determination of indications for various CLL therapy programs with the aim of increasing their clinical effectiveness. Material and methods. The research presents the data on chromosomal aberrations with the help of the FISH method in 224 CLL patients during the diagnosis, among them 49 patients are in stage A, 166 patients - in stage B and 29 patients - in stage C. Results and discussion. Chromosomal abnormalities were detected in 176 (72 %) patients. The most frequent aberration in CLL was del13q14, which was found in 124 (51 %) patients and occurred alone or in combination with other chromosomal changes. As the only chromosomal abnormality, del13q14 was found in 77 patients who differed from each other in the number of tumor cells that had isolated del13q14. We have studied the prognostic value of the content of tumor cells with isolated 13q14 deletion in CLL patients during the diagnosis. A comparative analysis of 2 groups of patients who had the percentage of leukemia cells with this deletion (it was ≥ 60 % or < 60 %) was conducted. It has been established that the number of cells with isolated del13q14 is an independent predictor of survival, free from treatment, as well as the overall survival of CLL patients and may serve as an additional prognostic factor.
|
